101 related articles for article (PubMed ID: 2125213)
1. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.
Rabbani SA; Desjardins J; Bell AW; Banville D; Mazar A; Henkin J; Goltzman D
Biochem Biophys Res Commun; 1990 Dec; 173(3):1058-64. PubMed ID: 2125213
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.
Koutsilieris M; Frenette G; Lazure C; Lehoux JG; Govindan MV; Polychronakos C
Anticancer Res; 1993; 13(2):481-6. PubMed ID: 7685989
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the development of osteoblastic metastases.
Goltzman D
Cancer; 1997 Oct; 80(8 Suppl):1581-7. PubMed ID: 9362425
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
5. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.
Koutsilieris M; Sourla A; Pelletier G; Doillon CJ
J Bone Miner Res; 1994 Nov; 9(11):1823-32. PubMed ID: 7863832
[TBL] [Abstract][Full Text] [Related]
8. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator.
Nolli ML; Corti A; Soffientini A; Cassani G
Thromb Haemost; 1986 Oct; 56(2):214-8. PubMed ID: 2433787
[TBL] [Abstract][Full Text] [Related]
10. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.
Koutsilieris M; Reyes-Moreno C; Sourla A; Dimitriadou V; Choki I
Anticancer Res; 1997; 17(3A):1461-5. PubMed ID: 9179184
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
12. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Achbarou A; Kaiser S; Tremblay G; Ste-Marie LG; Brodt P; Goltzman D; Rabbani SA
Cancer Res; 1994 May; 54(9):2372-7. PubMed ID: 8162583
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
14. The effect of transforming growth factor beta on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63.
Fawthrop FW; Oyajobi BO; Bunning RA; Russell RG
J Bone Miner Res; 1992 Dec; 7(12):1363-71. PubMed ID: 1481722
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton.
Reyes-Moreno C; Koutsilieris M
Clin Exp Metastasis; 1997 May; 15(3):205-17. PubMed ID: 9174122
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Ray P; Bhatti R; Gadarowski J; Bell N; Nasruddin S
Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
[TBL] [Abstract][Full Text] [Related]
17. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3.
Liu DF; Rabbani SA
Prostate; 1995 Nov; 27(5):269-76. PubMed ID: 7479394
[TBL] [Abstract][Full Text] [Related]
18. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.
Rabbani SA; Gladu J; Mazar AP; Henkin J; Goltzman D
J Cell Physiol; 1997 Aug; 172(2):137-45. PubMed ID: 9258335
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.
Corti A; Nolli ML; Soffientini A; Cassani G
Thromb Haemost; 1986 Oct; 56(2):219-24. PubMed ID: 3101222
[TBL] [Abstract][Full Text] [Related]
20. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
